ScandiBio Therapeutics AB Initiates Phase 3 Clinical Trial for Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia, leading to memory loss and cognitive impairments that interfere with daily life.
A growing body of evidence suggests that impaired brain energy metabolism and mitochondrial dysfunction contribute to cognitive decline in AD.
Impaired brain energy metabolism and mitochondrial dysfunction may contribute to cognitive decline in AD.
Trial Overview
The phase 3 clinical trial aims to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug.
- Multicentre trial across nine clinical centres in Turkey
- Targets patients with mild, moderate, and severe Alzheimer's symptoms
Author's summary: ScandiBio initiates phase 3 trial for Alzheimer's disease treatment.